For the year ending 2025-12-31, DNABW made $170,155K in revenue. -$309,106K in net income. Net profit margin of -181.66%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 170,155 | |||
| Cost of revenue-Service | 31,521 | |||
| Cost of revenue-Product | 0 | |||
| Cost of revenue-Product And Service Other | 15,451 | |||
| Research and development | 243,773 | |||
| General and administrative | 183,290 | |||
| Impairment of lease assets | 0 | |||
| Goodwill impairment | 0 | |||
| Restructuring charges | 11,398 | |||
| Total operating expenses | 485,433 | |||
| Loss from operations | -315,278 | |||
| Interest income | 22,616 | |||
| Interest expense | 0 | |||
| Loss on equity method investments | 0 | |||
| Loss on investments | -16,411 | |||
| Loss on deconsolidation of subsidiaries | 0 | |||
| Change in fair value of warrant liabilities | 0 | |||
| Other (expense) income, net | -4,527 | |||
| Total other income (expense) | 1,678 | |||
| Loss before income taxes | -313,600 | |||
| Income tax benefit | -837 | |||
| Net loss | -312,763 | |||
| Foreign currency translation adjustment | 3,531 | |||
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | 0 | |||
| Unrealized gain on available-for-sale securities | -126 | |||
| Total other comprehensive income (loss) | 3,657 | |||
| Comprehensive loss | -309,106 | |||
| Basic EPS | -5.64 | |||
| Diluted EPS | -5.64 | |||
| Basic Average Shares | 55,457,676 | |||
| Diluted Average Shares | 55,457,676 | |||
Ginkgo Bioworks Holdings, Inc. (DNABW)
Ginkgo Bioworks Holdings, Inc. (DNABW)